CP-532,903
CP-532,903
CP-532,903 (pronunciation: C-P-five-three-two-nine-zero-three) is a pharmaceutical drug developed by Pfizer for the potential treatment of myocardial infarction, also known as a heart attack.
Etymology
The name "CP-532,903" is a unique identifier given by the developing company, Pfizer. The "CP" stands for Central Pharmaceuticals, a division of Pfizer. The number "532,903" is a sequential number assigned to the compound during its development.
Mechanism of Action
CP-532,903 is a selective adenosine A3 receptor agonist. Adenosine A3 receptors are a subtype of adenosine receptors, which are a group of G protein-coupled receptors with adenosine as their endogenous ligand. By activating these receptors, CP-532,903 can increase coronary blood flow, reduce myocardial oxygen consumption, and limit the size of a myocardial infarction.
Related Terms
- Pharmaceutical drug
- Pfizer
- Myocardial infarction
- Adenosine A3 receptor
- Adenosine receptors
- G protein-coupled receptors
- Myocardial oxygen
External links
- Medical encyclopedia article on CP-532,903
- Wikipedia's article - CP-532,903
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski